Autism-Like Behavior in BTBR Mice Is Improved by Electroconvulsive Therapy

Neurotherapeutics

Volumn 12, Issue 3, 2015, Pages 657-666

  Hagen, Eunice ^a   Shprung, Dana ^a   Minakova, Elena ^a   Washington, James ^a   Kumar, Udaya ^a   Shin, Don ^a   Sankar, Raman ^a   Mazarati, Andrey ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Autism; BTBR mice; Electroconvulsive therapy; Oxytocin; Oxytocin receptor blocker

Indexed keywords

2 AMINO N [ 7,7 DIMETHYL 1 [[( 4 ( 2 METHYLPHENYL) 1 PIPERAZINYL)SULFONYL]METHYL]BICYCLO[2.2.1]HEPT 2 YL] 4 (METHYLSULFONYL)BUTANAMIDE; OXYTOCIN ANTAGONIST; UNCLASSIFIED DRUG; BORNANE DERIVATIVE; L 368899; OXTR PROTEIN, MOUSE; OXYTOCIN RECEPTOR; PIPERAZINE DERIVATIVE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; AUTISM; BEHAVIOR DISORDER; COMPULSION; CONTROLLED STUDY; DRUG INFUSION; ELECTRIC SHOCK; ELECTROCONVULSIVE THERAPY; LATERAL BRAIN VENTRICLE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SOCIAL BEHAVIOR; SOCIAL DISABILITY; SOCIAL NOVELTY; SOCIALIZATION; THERAPY EFFECT; ANIMAL; ANTAGONISTS AND INHIBITORS; AUTISTIC DISORDER; C57BL MOUSE; DISEASE MODEL; DRUG EFFECTS; INBRED MOUSE STRAIN; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; PHYSIOLOGY; PSYCHOLOGY; TREATMENT OUTCOME;

ANIMALS; AUTISTIC DISORDER; BEHAVIOR, ANIMAL; BORNANES; DISEASE MODELS, ANIMAL; ELECTROCONVULSIVE THERAPY; INFUSIONS, INTRAVENTRICULAR; MICE; MICE, INBRED C57BL; MICE, INBRED STRAINS; PIPERAZINES; RECEPTORS, OXYTOCIN; SOCIAL BEHAVIOR; TREATMENT OUTCOME;

EID: 84937631148     PISSN: 19337213     EISSN: 18787479     Source Type: Journal    
DOI: 10.1007/s13311-015-0357-7     Document Type: Article

References (59)

1. Diagnostic and Statistical Manual of Mental Disorders V. American Psychiatric Association, Washington, DC, 2013.
2. Chadman KK, Guariglia SR, Yoo JH. New directions in the treatment of autism spectrum disorders from animal model research. Expert Opin Drug Discov 2012;7:407-416.
3. Ruskin DN, Svedova J, Cote JL, et al. Ketogenic diet improves core symptoms of autism in BTBR mice. PLoS One 2013;8:e65021.
4. Napoli E, Duenas N, Giulivi C. Potential therapeutic use of the ketogenic diet in autism spectrum disorders. Front Pediatr 2014;2:69.
5. Mazarati A, Washington III JA, Sankar R, Shin D, Kumar U. Interaction between recurrent seizures and autism-like behavior in a mouse model of maternal immune activation. American Epilepsy Society Annual Meeting 2014: Abstract # 1.056.
6. Mazzone L, Postorino V, Valeri G, Vicari S. Catatonia in patients with autism: prevalence and management. CNS Drugs 2014;28:205-215.
7. Wachtel LE, Jaffe R, Kellner CH. Electroconvulsive therapy for psychotropic-refractory bipolar affective disorder and severe self-injury and aggression in an 11-year-old autistic boy. Eur Child Adolesc Psychiatry 2011;20:147-152.
8. Zaw FK, Bates GD, Murali V, Bentham P. Catatonia, autism, and ECT. Dev Med Child Neurol 1999;41:843-845.
9. Dhossche DM, Stanfill S. Could ECT be effective in autism? Med Hypotheses 2004;63:371-376.
10. Wachtel LE, Dhossche DM, Kellner CH. When is electroconvulsive therapy appropriate for children and adolescents? Med Hypotheses 2011;76:395-399.
11. Nyffeler J, Walitza S, Bobrowski E, Gundelfinger R, Grunblatt E. Association study in siblings and case-controls of serotonin- and oxytocin-related genes with high functioning autism. J Mol Psychiatry 2014;2:1.
12. Parker KJ, Garner JP, Libove RA, et al. Plasma oxytocin concentrations and OXTR polymorphisms predict social impairments in children with and without autism spectrum disorder. Proc Natl Acad Sci U S A 2014;111:12258-12263.
13. Striepens N, Kendrick KM, Maier W, Hurlemann R. Prosocial effects of oxytocin and clinical evidence for its therapeutic potential. Front Neuroendocrinol 2011;32:426-450.
14. Modi ME, Young LJ. The oxytocin system in drug discovery for autism: animal models and novel therapeutic strategies. Horm Behav 2012;61:340-350.
15. Pobbe RL, Pearson BL, Blanchard DC, Blanchard RJ. Oxytocin receptor and Mecp2 308/Y knockout mice exhibit altered expression of autism-related social behaviors. Physiol Behav 2012;107:641-648.
16. Teng BL, Nonneman RJ, Agster KL, et al. Prosocial effects of oxytocin in two mouse models of autism spectrum disorders. Neuropharmacology 2013;72:187-196.
17. Sun Q, Pretel S, Applegate CD, Piekut DT. Oxytocin and vasopressin mRNA expression in rat hypothalamus following kainic acid-induced seizures. Neuroscience 1996;71:543-554.
18. Gur E, Dremencov E, Garcia F, et al. Functional effects of chronic electroconvulsive shock on serotonergic 5-HT(1A) and 5-HT(1B) receptor activity in rat hippocampus and hypothalamus. Brain Res 2002;952:52-60.
19. McFarlane HG, Kusek GK, Yang M, et al. Autism-like behavioral phenotypes in BTBR T + tf/J mice. Genes Brain Behav 2008;7:152-163.
20. Sforazzini F, Bertero A, Dodero L, et al. Altered functional connectivity networks in acallosal and socially impaired BTBR mice. Brain Struct Funct 2014.
21. Crawley JN. Chapter 9. Social Behaviors. In: Craige CP (ed.) What's wrong with my mousee? Wiley Interscience, Hoboken, NJ, 2007, pp. 206-224.
22. Pineda E, Shin D, You SJ, et al. Maternal immune activation promotes hippocampal kindling epileptogenesis in mice. Ann Neurol 2013;74:11-19.
23. Smith SE, Li J, Garbett K, Mirnics K, Patterson PH. Maternal immune activation alters fetal brain development through interleukin-6. J Neurosci 2007;27:10695-10702.
24. Malkova NV, Yu CZ, Hsiao EY, Moore MJ, Patterson PH. Maternal immune activation yields offspring displaying mouse versions of the three core symptoms of autism. Brain Behav Immun 2012;26:607-616.
25. Sakaida M, Sukeno M, Imoto Y, et al. Electroconvulsive seizure-induced changes in gene expression in the mouse hypothalamic paraventricular nucleus. J Psychopharmacol 2013;27:1058-1069.
26. Weber T, Baier V, Lentz K, et al. Genetic fate mapping of type-1 stem cell-dependent increase in newborn hippocampal neurons after electroconvulsive seizures. Hippocampus 2013;23:1321-1330.
27. Williams PD, Anderson PS, Ball RG, et al.1-((7,7-Dimethyl-2(S)-(2(S)-amino-4-(methylsulfonyl)butyramido)bicyclo [2.2.1]-heptan-1(S)-yl)methyl)sulfonyl)-4-(2-methylphenyl)piperaz ine (L-368,899): an orally bioavailable, non-peptide oxytocin antagonist with potential utility for managing preterm labor.J Med Chem 1994;37:565-571.
28. Paxinos G, Franklin BJ. The mouse brain in stereotaxic coordinates. Academic Press, San Diego, CA, 2001.
29. Abbott CC, Gallegos P, Rediske N, Lemke NT, Quinn DK. A review of longitudinal electroconvulsive therapy: neuroimaging investigations. J Geriatr Psychiatry Neurol 2014;27:33-46.
30. Spaans HP, Kho KH, Verwijk E, Kok RM, Stek ML. Efficacy of ultrabrief pulse electroconvulsive therapy for depression: a systematic review. J Affect Disord 2013;150:720-726.
31. Kellner CH, Greenberg RM, Murrough JW, et al. ECT in treatment-resistant depression. Am J Psychiatry 2012;169:1238-1244.
32. Versiani M, Cheniaux E, Landeira-Fernandez J. Efficacy and safety of electroconvulsive therapy in the treatment of bipolar disorder: a systematic review. J ECT 2011;27:153-164.
33. Pompili M, Lester D, Dominici G, et al. Indications for electroconvulsive treatment in schizophrenia: a systematic review. Schizophr Res 2013;146:1-9.
34. Zervas IM, Theleritis C, Soldatos CR. Using ECT in schizophrenia: a review from a clinical perspective. World J Biol Psychiatry 2012;13:96-105.
35. Sackeim HA. The anticonvulsant hypothesis of the mechanisms of action of ECT: current status. J ECT 1999;15:5-26.
36. Segi-Nishida E. Exploration of new molecular mechanisms for antidepressant actions of electroconvulsive seizure. Biol Pharm Bull 2011;34:939-944.
37. Rotheneichner P, Lange S, O'Sullivan A, et al. Hippocampal neurogenesis and antidepressive therapy: shocking relations. Neural Plast 2014;2014:723915.
38. Wachtel LE, Reti IM, Dhossche DM, Slomine BS, Sanz J. Stability of neuropsychological testing during two years of maintenance electroconvulsive therapy in an autistic man. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:301-302.
39. Fisher P. Psychological factors related to the experience of and reaction to electroconvulsive therapy. J Ment Health 2012;21:589-599.
40. Philpot M, Treloar A, Gormley N, Gustafson L. Barriers to the use of electroconvulsive therapy in the elderly: a European survey. Eur Psychiatry 2002;17:41-45.
41. Dodero L, Damiano M, Galbusera A, et al. Neuroimaging evidence of major morpho-anatomical and functional abnormalities in the BTBR T + TF/J mouse model of autism. PLoS One 2013;8:e76655.
42. Wahlsten D, Metten P, Crabbe JC. Survey of 21 inbred mouse strains in two laboratories reveals that BTBR T/+ tf/tf has severely reduced hippocampal commissure and absent corpus callosum. Brain Res 2003;971:47-54.
43. Paul LK, Brown WS, Adolphs R, et al. Agenesis of the corpus callosum: genetic, developmental and functional aspects of connectivity. Nat Rev Neurosci 2007;8:287-299.
44. Badaruddin DH, Andrews GL, Bolte S, et al. Social and behavioral problems of children with agenesis of the corpus callosum. Child Psychiatry Hum Dev 2007;38:287-302.
45. Lau YC, Hinkley LB, Bukshpun P, et al. Autism traits in individuals with agenesis of the corpus callosum. J Autism Dev Disord 2013;43:1106-1118.
46. Yang M, Clarke AM, Crawley JN. Postnatal lesion evidence against a primary role for the corpus callosum in mouse sociability. Eur J Neurosci 2009;29:1663-1677.
47. Zikopoulos B, Barbas H. Altered neural connectivity in excitatory and inhibitory cortical circuits in autism. Front Hum Neurosci 2013;7:609.
48. Meziane H, Schaller F, Bauer S, et al. An early postnatal oxytocin treatment prevents social and learning deficits in adult mice deficient for Magel2, a gene involved in Prader-Willi syndrome and autism. Biol Psychiatry 2014.
49. Riddle WJ, Scott AI, Bennie J, Carroll S, Fink G. Current intensity and oxytocin release after electroconvulsive therapy. Biol Psychiatry 1993;33:839-841.
50. Smith JE, Williams K, Burkett S, Glue P, Nutt DJ. Oxytocin and vasopressin responses to ECT. Psychiatry Res 1990;32:201-202.
51. Devanand DP, Lisanby S, Lo ES, et al. Effects of electroconvulsive therapy on plasma vasopressin and oxytocin. Biol Psychiatry 1998;44:610-616.
52. Silverman JL, Yang M, Turner SM, et al. Low stress reactivity and neuroendocrine factors in the BTBR T + tf/J mouse model of autism. Neuroscience 2010;171:1197-1208.
53. Bales KL, Solomon M, Jacob S, et al. Long-term exposure to intranasal oxytocin in a mouse autism model. Transl Psychiatry 2014;4:e480.
54. Hollander E, Novotny S, Hanratty M, et al. Oxytocin infusion reduces repetitive behaviors in adults with autistic and Asperger's disorders. Neuropsychopharmacology 2003;28:193-198.
55. Miller M, Bales KL, Taylor SL, et al. Oxytocin and vasopressin in children and adolescents with autism spectrum disorders: sex differences and associations with symptoms. Autism Res 2013;6:91-102.
56. Kalueff AV, Tuohimaa P. Contrasting grooming phenotypes in three mouse strains markedly different in anxiety and activity (129S1, BALB/c and NMRI). Behav Brain Res 2005;160:1-10.
57. Calcagnoli F, de Boer SF, Althaus M, den Boer JA, Koolhaas JM. Antiaggressive activity of central oxytocin in male rats. Psychopharmacology (Berl) 2013;229:639-651.
58. Sala M, Braida D, Lentini D, et al. Pharmacologic rescue of impaired cognitive flexibility, social deficits, increased aggression, and seizure susceptibility in oxytocin receptor null mice: a neurobehavioral model of autism. Biol Psychiatry 2011;69:875-882.
59. Francis SM, Sagar A, Levin-Decanini T, et al. Oxytocin and vasopressin systems in genetic syndromes and neurodevelopmental disorders. Brain Res 2014;1580:199-218.